Patients who need PCSK9 inhibitors can’t get them April 29, 2017By Tracey WalkerStudy: PCSK9 inhibitors are being rejected by insurers at very high rates even in high-risk patients like those with familial hypercholesterolemia. Game-changing cholesterol-buster further reduces heart attack, stroke April 16, 2017By Tracey WalkerA new outcomes study shows that the PCSK9 inhibitor Repatha significantly reduced the risk of hard major adverse cardiovascular events in high-risk patients by 20%. Partnership aims to make insulin more affordable April 14, 2017By Tracey WalkerCVS, Novo Nordisk launch a prescription savings program to help patients afford essential medications. Prescribing practices that increase risk of opioid overdose April 11, 2017By Tracey WalkerTwo studies, one from Prime Therapeutics and Stanford, reveal an alarming increase in overdose with concurrent use of opioids and benzodiazepines. Here’s how managed care can help. Prevent polypharmacy problems April 08, 2017By Mari EdlinPolypharmacy presents real problems—especially for older adults. New therapies show promise in treating diabetesNew updates in insulin products, as well as non-pharma therapies are on the horizon for diabetes. Shifting trends in the pharmaceutical marketplace: What to watch March 31, 2017By Bryant FurlowFrom public furor over price hikes to the loss of patent protections for blockbuster drugs, big changes are afoot in the pharmaceutical marketplace. Read more. Incremental clinical advances for Duchenne Muscular Dystrophy March 31, 2017By Bryant FurlowJust last year, the FDA approved Exondys 51 (eteplirsen) for DMD, over the recommendations of FDA scientists and an external scientific advisory committee. Read more. Rapid oncology innovation raises management challenges for payers March 31, 2017By Bryant FurlowOncology is a complex and rapidly-evolving management challenge for payers. Top challenges likely to slow adoption of biosimilars March 31, 2017By Bryant FurlowBiosimilars will reshape clinical care and managed care pharmacy but ambiguities in the regulatory landscape and knowledge gaps among clinicians seem likely slow adoption.